has found a new solution for cost-effective production of a new nutritional health ingredient for human consumption.
The breakthrough is presented today at the company's capital markets day.
is streamlining the organisation and focusing on its core competence; sustainable krill harvesting, producing high-value ingredients and sales and marketing.
"We are shifting gear and focusing our efforts to make Aker BioMarine
even better in those areas where the potential for profitable growth are the biggest.
In Aker we are putting a lot of effort in to make Aker BioMarine succeed," says Leif-Arne Langøy, chairman of Aker BioMarine.
At Aker BioMarine's
capital markets day, the company is announcing three changes related to its future growth and direction.
The vessel Saga Sea has sufficient capacity to cover Aker BioMarine's
requirements for sustainable harvesting and on board production of krill meal, krill oil and the new krill powder.
The decision to focus purely on the krill business means Aker BioMarine's
fisheries business in Argentina and on the Faroe Islands will be spun off in a separate company.
It is proposed that the new fisheries business is sold to the existing shareholders in Aker BioMarine
Aker wants to maintain a holding of at least 82.9 per cent in the company that includes the operations in Argentina and on the Faeroe Islands, and the other shareholders in Aker BioMarine
will be offered the opportunity to maintain their relative holdings in the fishing company.
More information about the offer will be presented during the fourth quarter of 2008, with the aim of closing the transaction before the end of the year.
is still a start-up company.
At the capital markets day, Aker BioMarine
is presenting a four-point action plan to strengthen the focus on the company's core activities and improve the results.
In the Nordic market, Aker BioMarine
has a sales and marketing agreement with Life Europe for Superba™ krill oil.
This agreement covers more than 600 shops and outlets.
In January 2009, the company will start selling the new krill powder-based tablet directly to consumers in the US market.
These measures will reduce significantly Aker BioMarine's
debt and fixed costs.
"This means that Aker BioMarine
does not require any injection of additional capital.
Plese find presentations from Aker BioMarine's capital markets day.
Aaron Kramer, CFO and IR contact, Aker BioMarine, Tel: +47 24 13 01 30
Aker BioMarine ASA, Fjordalleen 16, P.o.Box 1423 Vika, 0115 Oslo, Norway, Phone: +47 24 13 00 00 - Fax: +47 24 13 01 10
- © 2012 Aker BioMarine